Ockham and etrials team up on EDC

By Gareth Macdonald

- Last updated on GMT

Related tags: Nasdaq, Stock market, Stock exchange

US CRO Ockham Development group will start providing customers with data capture and analysis solutions developed by etrials under a new, five year licensing agreement.

Ockham, which was bought by trial staffing specialist ASG in February, will offer etrials’ suite of “Trial Intelligence​” eClinical solutions, with a particular focus on providing platforms for use in adaptive trials.

Ockham president Joshua Baker explained that: “The addition of etrials’ adaptive solutions…increases our ability to provide an even greater breadth of integrated solutions with a highly flexible, robust EDC system delivered directly from us.”

Baker also stressed that by gaining access to the technology Ockham’s customers will be able to develop and deploy it for trials in a more flexible and reactive way, which he said will aid clinical development.

Under the deal, financial terms of which have not been released, etrials will also provide data hosting, training, development and technical support, as well sales and marketing services.

Denis Connaghan, etrial’s CEO, said the agreement “transfer[s] etrials’ knowledge of EDC design and deployment best practices and support and meet their sponsors’ clinical trial development requirements more holistically​.”

etrials faces Nasdaq delisting

The Ockham deal and the potential extra customers and revenue it will generate for etrials, will not have escaped the attention of any of the firms currently pursuing a takeover.

On May 11 Bio-Imaging Technologies, also known as BioClinica, upped its bid for North Carolina headquartered etrials to some $15m after reports that an unidentified third company was considering a move for the EDC specialist.

Speaking at the time Mark Weinstein, CEO of BioClinica said: "etrials is an excellent fit with our long-term corporate strategy. This addition instantly broadens our eClinical product offering while leveraging our global operations​.”

While further details of the rival bidder are yet to emerge, etrials will be hoping that any takeover bid happens sooner rather than later.

On May 22 the firm announced that it faces delisting from the Nasdaq Stock Market because it no longer complies with a rule requiring minimum stockholders’ equity of $10m

etrials, which reported stock holder equity of $9.6m for the three months ended March 31, said it is “currently preparing its plan for compliance with Nasdaq Global Market listing requirements and expects to submit the plan to Nasdaq by the June 2​”.

Related news

Show more

Related products

show more

What’s Next for mRNA?

What’s Next for mRNA?

Catalent Pharma Solutions | 27-Jan-2022 | Insight Guide

Now that the pharma industry and regulators have significant data on safety and efficacy of mRNA vaccines, many companies are looking beyond infectious...

SmartSignals Study Oversight

SmartSignals Study Oversight

Signant Health | 24-Jan-2022 | Product Brochure

Today, sponsors and study teams often struggle to support the growing variety and volume of clinical data. The right technology thought will help your...

The APAC Advantages

The APAC Advantages

Catalent Pharma Solutions | 18-Jan-2022 | Insight Guide

Over recent years, the Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies.

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars